Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.


http://dlvr.it/T6XDWG

Comments

Popular posts from this blog

Bustos on Bloomberg TV: In Last Two Weeks, “Price of Gas Has Gone Down Forty Cents”

Bustos Announces More Than $7.1 Million in Federal Funding for Peoria Head Start